Table 4.

Clinical predictors of progestin treatment response in total cohort (n = 71).

OR (95% CI)P
Univariable analysis
Age (years)0.98 (0.9–1.0)0.11
Baseline BMI (kg/m2)1.00 (0.9–1.1)0.98
Postmenopausal
 No1
 Yes0.51 (0.2–1.4)0.19
PCOS
 No1
 Yes1.58 (0.5–5.2)0.45
T2DM
 No1
 Yes0.70 (0.3–2.0)0.49
Histology
 Endometrial cancer1
 Atypical hyperplasia2.88 (1.0–8.0)0.04b
Endometrial mass lesion
 No1
 Yes0.68 (0.2–3.1)0.61
Myometrial invasion
 No1
 Yes0.76 (1.4–4.2)0.75
Bariatric surgery
 No1
 Yes1.78 (0.6–5.2)0.29
% change in total body weighta
 <10%1
 ≥10%3.26 (1.1–9.9)0.04b
Multivariable analysis adjusted for age, T2DM, histology, % change in total body weight
Histology
 Endometrial cancer1
 Atypical hyperplasia3.52 (1.1–11.0)0.03b
% change in total body weighta
 <10%1
 >10%3.95 (1.3–12.5)0.02b
  • aExcludes the n = 5 women who progressed during progestin treatment.

  • bSignificant at P < 0.05.